Open an account

Protagenic Therapeutics

PTIX · NASDAQ

$0.75−$0.03 (−3.85%)TodayMarket closed ·
No price history for this range.

About PTIX

Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The firm has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The firm's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The firm's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The firm's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.

Employees
1
Headquarters
New York City, New York
Listed
Dec 18, 1996
Sector
Health Care
Industry
Biotechnology
Website
protagenic.com

PTIX key statistics

Market cap
1.36M
Price-earnings ratio
0.34
Dividend yield
—
Average volume
1.36K
Volume
31
Open price
$0.7625
High today
$0.7625
Low today
$0.75
52 Week high
$3.27
52 Week low
$0.1282

Protagenic Therapeutics (PTIX) at a glance

Protagenic Therapeutics (PTIX) last traded at $0.75, with a market cap of 1.36M and a price-to-earnings ratio of 0.34.

Today the stock has traded between $0.75 and $0.7625. The current price is 0.0% above the day's low and 1.6% below its high.

Volume so far is 31 shares, below the average of 1.36K shares a day.

Over the past year Protagenic Therapeutics has ranged from $0.1282 to $3.27, and now sits 20% of the way up that range.

Protagenic Therapeutics met or beat analyst EPS estimates in 2 of the last 6 quarters. In Q1 FY25 it reported -$2.75 per share against an estimate of $0.00.

PTIX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 6 quarters, by 41.0% on average.

  1. Q3 FY21: reported -$2.80 per share against an estimate of -$4.57
  2. Q4 FY21: reported -$2.91 per share against an estimate of -$5.14
  3. Q3 FY23: reported -$0.32 per share against an estimate of $0.00
  4. Q2 FY24: reported -$0.36 per share against an estimate of $0.00
  5. Q4 FY24: reported -$0.24 per share against an estimate of $0.00
  6. Q1 FY25: reported -$2.75 per share against an estimate of $0.00

PTIX news

  • Henry Khederian

    Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress

  • Avi Kapoor

    S&P 500 Moves Lower; Walmart Shares Fall After Q2 Results

  • Avi Kapoor

    Dow Dips Over 100 Points; US Initial Jobless Claims Increase

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, TXNM, SVT, PTIX on Behalf of Shareholders

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    Nasdaq Falls 100 Points; Home Depot Sales Top Views

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

Similar companies

Companies in the same industry as Protagenic Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.